Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00602147 · ClinicalTrials.gov registry record
Studying Common Genetic Mutations Related to Mucositis in Patients With Multiple Myeloma Receiving High-Dose Melphalan
A clinical trial, sponsored by Vanderbilt-Ingram Cancer Center.
- Terminated
- Registry status
- 95
- Enrollment target
NCT00602147 is a clinical trial that was terminated before completion, run by Vanderbilt-Ingram Cancer Center. The registered enrollment target is 95 participants.
The verdict
NCT00602147 was terminated before completion, sponsored by Vanderbilt-Ingram Cancer Center.
- TERMINATED
- Registry status
- 95 participants
- Enrollment target
Study Summary
RATIONALE: Studying blood or mouthwash samples in the laboratory from patients receiving melphalan for cancer may help doctors learn more about changes that occur in DNA, identify biomarkers related to cancer, and help predict how patients will respond to treatment. PURPOSE: This clinical trial is studying common genetic mutations related to mucositis in patients with multiple myeloma receiving high-dose melphalan.
Interventions
- OTHER laboratory biomarker analysis
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 95 participants |
| Start Date | 2007-07 |
| Est. Completion | 2010-04 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00602147
The ClinicalTrials.gov registry entry for NCT00602147 describes a study currently listed as terminated, categorized as an unspecified phase. The registered enrollment target is 95 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Vanderbilt-Ingram Cancer Center, which has 189 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which laboratory biomarker analysis is the first listed.
NCT00602147 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00602147 about?
NCT00602147 is a clinical study titled "Studying Common Genetic Mutations Related to Mucositis in Patients With Multiple Myeloma Receiving High-Dose Melphalan". RATIONALE: Studying blood or mouthwash samples in the laboratory from patients receiving melphalan for cancer may help doctors learn more about changes that occur in DNA, identify biomarkers related to cancer, and help predict how patients will respond to treatment. PURPOSE: This clinical trial is ...
What is the current status of trial NCT00602147?
This trial is currently terminated. The enrollment target is 95 participants. The study started on 2007-07. Estimated completion is 2010-04.
What interventions are being tested in trial NCT00602147?
The interventions under investigation include: laboratory biomarker analysis (OTHER).
Who is sponsoring clinical trial NCT00602147?
This trial is sponsored by Vanderbilt-Ingram Cancer Center, which has 189 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.